Glucagonoma natural history, complications and prognosis

Revision as of 20:13, 1 August 2017 by Medhat (talk | contribs)
Jump to navigation Jump to search

Glucagonoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Glucagonoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glucagonoma natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glucagonoma natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glucagonoma natural history, complications and prognosis

CDC on Glucagonoma natural history, complications and prognosis

Glucagonoma natural history, complications and prognosis in the news

Blogs on Glucagonoma natural history, complications and prognosis

Directions to Hospitals Treating Glucagonoma

Risk calculators and risk factors for Glucagonoma natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

If left untreated, patients with glucagonoma may progress to develop necrolytic migratory erythema, cheilosis, stomatitis, diarrhea, polyuria, and polydipsia. The presence of metastasis is associated with a particularly poor prognosis among patients with glucagonoma. The 10 year event free survival rate is less than 51.6% with metastasis and 64.3% without metastasis.

Natural History

Prognosis

PROGNOSIS 

Glucagonomas are generally slow-growing, but are usually advanced by the time of diagnosis.

The most common site of metastasis is the liver, followed by regional lymph nodes, bone, adrenal gland, kidney, and lung.

Age, grade, and distant metastases are the most significant predictors of survival.

Once the tumor is metastatic, cure is rarely,

Five- and 10-year survival rates for patients undergoing resection of gastroenteropancreatic neuroendocrine tumors [2,12]

For approximately 60% of these tumors are cancerous, the prognosis of glucagonoma depends on the following:

  • Whether or not the tumor can be removed by surgery
  • The stage of the tumor, the size of the tumor, whether the cancer has spread outside the pancreas
  • The patient’s general health
  • Whether the tumor has just been diagnosed or has recurred
  • The presence of metastasis is associated with a particularly poor prognosis among patients with glucagonoma. The 10 year event free survival rate is less than 51.6% with metastasis and 64.3% without metastasis

References


Template:WikiDoc Sources